HS
PTGX icon

HighVista Strategies’s Protagonist Therapeutics PTGX Stock Holding History

HighVista Strategies’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3M Sell
24,460
-9,392
-28% -$981K 0.68% 46
2026
Q1 		$3.57M Sell
33,852
-39,693
-54% -$3.51M 0.99% 28
2025
Q4 		$6.42M Sell
73,545
-48,137
-40% -$3.94M 1.65% 14
2025
Q3 		$8.08M Buy
121,682
+63,831
+110% +$3.63M 1.98% 6
2025
Q2 		$3.2M Sell
57,851
-20,601
-26% -$989K 1.18% 14
2025
Q1 		$3.79M Buy
78,452
+15,934
+25% +$668K 1.46% 6
2024
Q4 		$2.41M Sell
62,518
-26,990
-30% -$1.18M 0.9% 30
2024
Q3 		$4.03M Buy
89,508
+68,279
+322% +$2.76M 1.39% 12
2024
Q2 		$736K Hold
21,229
– – 0.27% 106
2024
Q1 		$614K Sell
21,229
-7,130
-25% -$194K 0.22% 111
2023
Q4 		$650K Buy
+28,359
New +$496K 0.24% 107
2023
Q3 		– Sell
-29,179
Closed -$806K – 158
2023
Q2 		$806K Buy
+29,179
New +$730K 0.37% 66
2022
Q3 		– Sell
-46,459
Closed -$367K – 125
2022
Q2 		$367K Sell
46,459
-45,586
-50% -$551K 0.22% 84
2022
Q1 		$2.18M Buy
92,045
+61,046
+197% +$1.72M 1.39% 20
2021
Q4 		$1.06M Buy
30,999
+2,688
+9% +$85K 0.84% 42
2021
Q3 		$501K Buy
28,311
+2,458
+10% +$105K 0.33% 71
2021
Q2 		$1.16M Buy
+25,853
New +$853K 0.82% 17

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

HighVista Strategies's PTGX Position: Q2 2026 in Review

HighVista Strategies reduced its Protagonist Therapeutics (PTGX) stake by 28% in Q2 2026, selling an estimated $981K and leaving 24,460 shares worth $3M. The position accounts for 0.68% of the portfolio, ranked #46.

HighVista Strategies first reported a position in PTGX in Q2 2021 and has held it in 17 quarters since. The position peaked at $8.08M in Q3 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • HighVista Strategies held 24,460 shares of Protagonist Therapeutics worth $3M as of Q2 2026.
  • HighVista Strategies sold 9,392 Protagonist Therapeutics shares in Q2 2026, an estimated $981K.
  • Protagonist Therapeutics made up 0.68% of HighVista Strategies's portfolio in Q2 2026, its #46 holding.
  • HighVista Strategies first reported a position in Protagonist Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • HighVista Strategies's Protagonist Therapeutics position peaked at $8.08M in Q3 2025.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.